The Impact of Intravenous Iron Supplementation on Hematinic Parameters and Erythropoietin Requirements in Hemodialysis Patients
ConclusionHigh-dose intravenous iron (400 mg/week) can reduce the mean dose of rhEPO requirements and increase the TSAT index over a period of 6 months in hemodialysis patients. High-dose IV iron administration can decrease cardiovascular events in hemodialysis patients with iron deficiency anemia.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
More News: Anemia | Cardiology | Cardiovascular | Chronic Kidney Disease | Clinical Trials | Dialysis | Drugs & Pharmacology | Heart | Hemodialysis | Iran Health | Iron | Middle East Health | Stroke | Study | Urology & Nephrology